Nancy Simonian, MD, CEO, Syros Pharmaceuticals details the research of Richard A. Young of the Whitehead Institute and his discovery of super-enhancers, large groups of transcriptional enhancers that drive expression of genes that define cell identity. The research, which has revealed many previously unknown oncogenic drivers, may be important for future cancer therapies.